Pharmaceutical composition and application patent

Today’s cyclodextrin is an interesting application proposed by RemeGen Biosciences, which uses methyl-BCD to remarkably improve the pharmaceutical effect of antibody-drug conjugates. By using CDs, the ACD load can be lower, thus greatly reducing the production cost and the treatment cost of a patient.
If you are interested in similar solutions, check out Formulation development – www.carbohydesolutions.com

Espacenet – Pharmaceutical composition and application thereof

Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies

today’s cyclodextrin from Roquette:
Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
When subjected to light stress, adalimumab, as a model mAb, formulated in the presence of HPβCD, shows a significant decrease in protein aggregation and superior monomer and total protein recovery compared to PS 80-containing formulations. HPβCD also reduces both agitation and thermal stress-induced protein aggregation and prevents subvisible particle formation compared to PS 80. 
Hailong Zhang, Shiqi Hong, Tao PengKwan Hang LAMKeat Theng ChowRajeev Gokhale et al

See the article here: Polysorbates versus Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies